Adma Biologics (ADMA) Receivables - Net (2012 - 2026)

Adma Biologics (ADMA) has 14 years of Receivables - Net data on file, last reported at $158.4 million in Q4 2025.

• Quarterly Receivables - Net rose 216.86% year-over-year to $158.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $158.4 million (up 216.86% YoY) and the FY2025 annual result came in at $158.4 million, up 216.86% from the prior year.
• Receivables - Net rose to $158.4 million in Q4 2025, from $137.7 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $158.4 million in Q4 2025 to a low of $15.4 million in Q1 2021.
• A 5-year average of $48.8 million and a median of $29.3 million in 2021 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net sank 45.74% — and 2025, when it jumped 264.54%.
• Tracing ADMA's Receivables - Net over 5 years: stood at $28.6 million in 2021, then slumped by 45.74% to $15.5 million in 2022, then surged by 76.85% to $27.4 million in 2023, then soared by 82.34% to $50.0 million in 2024, then soared by 216.86% to $158.4 million in 2025.
• The last three Receivables - Net figures came in at $158.4 million (Q4 2025), $137.7 million (Q3 2025), and $109.7 million (Q2 2025), per Business Quant data.